Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer

British Journal of Cancer

Volumn 102, Issue 5, 2010, Pages 916-921

  Hamaya, Y ^a   Yoshida, K ^a   Takai, T ^b   Ikuma, M ^a   Hishida, A ^a   Kanaoka, S ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

Colorectal cancer; COX 2; Exfoliated cell; Faeces; RNA

Indexed keywords

BETA 2 MICROGLOBULIN; CARCINOEMBRYONIC ANTIGEN; CD45 ANTIGEN; CYCLOOXYGENASE 2; UVOMORULIN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; CADHERINS; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COHORT STUDIES; COLON; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77649270173     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605564     Document Type: Article

References (26)

1. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC (2000) Morphometric analysis of the 'mucocellular layer' overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 31: 51-57
2. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL (2008) Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 149: 441-450
3. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545
4. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (1989) Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334
5. Charbonneau H, Tonks NK, Walsh KA, Fischer EH (1988) The leukocyte common antigen (CD45): a putative receptor-linked protein tyrosine phosphatase. Proc Natl Acad Sci USA 85: 7182-7186
6. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97: 1124-1132
7. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR (1993) E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 142: 981-986
8. Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF (2006) Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 290: G1067-G1074
9. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, Sugihara K (1998) Size-and invasion-dependent increase in cyclooxygen-ase 2 levels in human colorectal carcinomas. Cancer Res 58: 4823-4826
10. Glockner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruine AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrugger RW, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE, Ahuja N (2009) Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 69: 4691-4699
11. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477
12. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351: 2704-2714
13. Kanaoka S, Takai T, Yoshida K (2007) Cyclooxygenase-2 and tumor biology. Adv Clin Chem 43: 59-78
14. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M (2004) Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 127: 422-427
15. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S (2008) Cyclo-oxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 8: 33
16. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Kozu T, Baba H, Matsumura Y (2008) Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci 99: 1977-1983
17. Lindholm E, Brevinge H, Haglind E (2008) Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 95: 1029-1036
18. Loktionov A (2007) Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int J Cancer 120: 2281-2289
19. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371
20. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y (2005) A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129: 422-428
21. Osborn NK, Ahlquist DA (2005) Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128: 192-206
22. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 55: 3785-3789
23. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD (2002) Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 50: 840-844
24. Sobin LH, Wittekind C (2002) Intenational Union Against Cancer (UICC). TNM Classification of Malignant Tumors. John Wiley & Sons, Inc: New York
25. John Wiley & Sons, Inc: New York Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, Sugimura H, Kajimura M, Hishida A (2009) Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 18: 1888-1893
26. Yu YJ, Majumdar AP, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, Kato I (2008) Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev 17: 455-458